dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Zanga, Gisela Mariel |
dc.contributor.author | Drzewiscki, Estefania |
dc.contributor.author | Tagliani, Paula |
dc.contributor.author | Smietniansky, Maximiliano |
dc.contributor.author | Esnaola Rojas, Maria M. |
dc.contributor.author | Caruso, Diego |
dc.date.accessioned | 2022-06-20T08:08:43Z |
dc.date.available | 2022-06-20T08:08:43Z |
dc.date.issued | 2021-10-05 |
dc.identifier.citation | Zanga G, Drzewiscki E, Tagliani P, Smietniansky M, Esnaola Rojas MM, et al. Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis. Ther Adv Neurol Disord. 2021 Oct 5;14:1–11. |
dc.identifier.issn | 1756-2864 |
dc.identifier.uri | https://hdl.handle.net/11351/7714 |
dc.description | Teràpies modificadores de la malaltia; Esclerosi múltiple; Predictors |
dc.description.sponsorship | The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GZ disclosed receipt of the following financial support for the research, authorship and/or publication of this article: this study was supported by a research grant awarded by the Florencio Fiorini Foundation. The article processing charges was funded by Roche. |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation.ispartofseries | Therapeutic Advances in Neurological Disorders;14 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Medicació oral |
dc.subject | Pacients - Cooperació |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Medication Adherence |
dc.subject.mesh | Administration, Oral |
dc.title | Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1177/17562864211031099 |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | adhesión a la medicación |
dc.subject.decs | administración oral |
dc.relation.publishversion | https://doi.org/10.1177/17562864211031099 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Zanga G] Department of Neurology, César Milstein Hospital, associated with University of Buenos Aires, Buenos Aires, Argentina. [Drzewiscki E, Esnaola Rojas MM] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Tagliani P] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Smietniansky M] Department of Internal Medicine Interna, Programa de Medicine Geriatric Program, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. [Caruso D] Department of Internal Medicine, César Milstein Hospital, associated with University of Buenos Aires, Buenos Aires, Argentina |
dc.identifier.pmid | 34630632 |
dc.identifier.wos | 000706298300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |